Dr Virginia Hebl, MD: Greetings. I'm Dr Virginia Hebl, advanced heart failure and transplant fellow at Mayo Clinic. During today's Mayo Clinic Talks podcast, we'll be discussing novel therapies to prevent vasculopathy following heart transplant. I'm joined by my colleague, Dr Sudhir Kushwaha, professor of medicine and the director of the Mayo Clinic Heart Transplant Program. Welcome, Dr Kushwaha.
Dr Sudhir S Kushwaha, MD: Thank you very much, Virginia. It's good to be here, and this is a subject that I've been very interested in for a long time and that I feel Mayo has contributed in significant ways to the medical literature and to the field in general.
Dr Hebl: We appreciate you being here and hearing your insights, if you don't mind covering the basics of cardiac allograft vasculopathy following cardiac transplantation.
Dr Kushwaha: Well, heart transplantation has been around for about 48 years now. You'd think that when you put a new heart into somebody who's got severe heart disease—severe heart failure—that that heart, if there's adequate immunosuppression, would last for many, many years. Unfortunately, that isn't the case. When we look at survival statisticswe can see that the survival at 10 years of patients undergoing heart transplant is about 60%.
Jan 05, 2024 This Week in Cardiology Podcast
How Surgeons Used a Double-Lung Transplant and a Pair of Breast Implants to Save a Young Man's Life
Physician-Owned Hospitals: The Answer for Better Care?
Bleeding Risk for Elective Cardiac Surgery Lower on Weekends
What Troponin Level Indicates Injury After Cardiac Surgery?
COMMENTARY
Sirolimus to Prevent Vasculopathy after Heart Transplant
Sudhir Kushwaha, MD; Virginia Hebl, MD
DisclosuresFebruary 22, 2016
Editorial Collaboration
Medscape &
Dr Virginia Hebl, MD: Greetings. I'm Dr Virginia Hebl, advanced heart failure and transplant fellow at Mayo Clinic. During today's Mayo Clinic Talks podcast, we'll be discussing novel therapies to prevent vasculopathy following heart transplant. I'm joined by my colleague, Dr Sudhir Kushwaha, professor of medicine and the director of the Mayo Clinic Heart Transplant Program. Welcome, Dr Kushwaha.
Dr Sudhir S Kushwaha, MD: Thank you very much, Virginia. It's good to be here, and this is a subject that I've been very interested in for a long time and that I feel Mayo has contributed in significant ways to the medical literature and to the field in general.
Dr Hebl: We appreciate you being here and hearing your insights, if you don't mind covering the basics of cardiac allograft vasculopathy following cardiac transplantation.
Dr Kushwaha: Well, heart transplantation has been around for about 48 years now. You'd think that when you put a new heart into somebody who's got severe heart disease—severe heart failure—that that heart, if there's adequate immunosuppression, would last for many, many years. Unfortunately, that isn't the case. When we look at survival statisticswe can see that the survival at 10 years of patients undergoing heart transplant is about 60%.
© 2016 Mayo Clinic
Cite this: Sudhir S. Kushwaha, Virginia Hebl. Sirolimus to Prevent Vasculopathy after Heart Transplant - Medscape - Feb 22, 2016.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author(s)
Sudhir S. Kushwaha
Professor of Medicine, Mayo Clinic College of Medicine, Director, Heart Transplant Clinic, Consultant, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Disclosure: Sudhir Kushwaha, MD, has disclosed no relevant financial relationships.
Virginia Hebl, MD
Instructor of Medicine, Mayo Clinic College of Medicine, Advanced Heart Failure and Transplant Cardiology Fellow, Mayo Clinic, Rochester, Minnesota.
Disclosure: Virginia Hebl, MD, has disclosed no relevant financial relationships.